The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion ...
Indeed, it's often described as a "wonder drug." That hasn’t stopped a torrent of fat phobia and often frankly hateful ...
A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...
In this week’s edition of InnovationRx, we look at HHS nominee Robert F. Kennedy Jr.’s first Senate confirmation hearing, the ...
The people of Greenland 'want to be with us', US President Donald Trump has said. The hadal zone, as scientists call it, is ...
Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...
Yet despite decades of research, no treatment has been created that arrests Alzheimer’s cognitive deterioration, let alone ...
Patients and care partners may find once every four weeks maintenance dosing easier The US Food and Drug Administration (FDA ... maintenance dosing of LEQEMBI (lecanemab-irmb) for early Alzheimer’s ...
Xenon is one of the six noble gases. Its name derives from the Greek word for “strange”. In medicine, it has been used as an ...
A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...